tbuckley/cabot-search huggingface dataset:
A community-sourced glossary of open scholarship terms
Authors: Sam Parsons, Flávio Azevedo, Mahmoud M. Elsherif, Samuel Guay, Owen N. Shahim, Gisela H. Govaart, Emma Norris, Aoife O’Mahony, Adam J. Parker, Ana Todorovic, Charlotte R. Pennington, Elias Garcia-Pelegrin, Aleksandra Lazić, Olly Robertson, Sara L. Middleton, Beatrice Valentini, Joanne McCuaig, Bradley J. Baker, Elizabeth Collins, Adrien A. Fillon, Tina B. Lonsdorf, Michele C. Lim, Norbert Vanek, Marton Kovacs, Timo B. Roettger, Sonia Rishi, Jacob F. Miranda, Matt Jaquiery, Suzanne L. K. Stewart, Valeria Agostini, Andrew J. Stewart, Kamil Izydorczak, Sarah Ashcroft-Jones, Helena Hartmann, Madeleine Ingham, Yuki Yamada, Martin R. Vasilev, Filip Dechterenko, Nihan Albayrak-Aydemir, Yu-Fang Yang, Annalise A. LaPlume, Julia K. Wolska, Emma L. Henderson, Mirela Zaneva, Benjamin G. Farrar, Ross Mounce, Tamara Kalandadze, Wanyin Li, Qinyu Xiao, Robert M. Ross, Siu Kit Yeung, Meng Liu, Micah L. Vandegrift, Zoltan Kekecs, Marta K. Topor, Myriam A. Baum, Emily A. Williams, Asma A. Assaneea, Amélie Bret, Aidan G. Cashin, Nick Ballou, Tsvetomira Dumbalska, Bettina M. J. Kern, Claire R. Melia, Beatrix Arendt, Gerald H. Vineyard, Jade S. Pickering, Thomas R. Evans, Catherine Laverty, Eliza A. Woodward, David Moreau, Dominique G. Roche, Eike M. Rinke, Graham Reid, Eduardo Garcia-Garzon, Steven Verheyen, Halil E. Kocalar, Ashley R. Blake, Jamie P. Cockcroft, Leticia Micheli, Brice Beffara Bret, Zoe M. Flack, Barnabas Szaszi, Markus Weinmann, Oscar Lecuona, Birgit Schmidt, William X. Ngiam, Ana Barbosa Mendes, Shannon Francis, Brett J. Gall, Mariella Paul, Connor T. Keating, Magdalena Grose-Hodge, James E. Bartlett, Bethan J. Iley, Lisa Spitzer, Madeleine Pownall, Christopher J. Graham, Tobias Wingen, Jenny Terry, Catia Margarida F. Oliveira, Ryan A. Millager, Kerry J. Fox, Alaa AlDoh, Alexander Hart, Olmo R. van den Akker, Gilad Feldman, Dominik A. Kiersz, Christina Pomareda, Kai Krautter, Ali H. Al-Hoorie, Balazs Aczel
Journal: Nature Human Behaviour (2022)
Clinical Endocrinology
Authors: James A. Pittman
Journal: JAMA (1970)

The house officer or medical student rotating through endocrinology should find this a useful introduction, and the older clinician will find it an interesting and easy-to-read review. The writing is crisp and rather dogmatic, with more care for getting points across than for presenting all the qualifying or uncertain aspects. It is not a comprehensive reference work, since there is no bibliographic support for most statements, even the controversial ones. On the other hand, it should prove a useful clinical guide to the clinician who does not deal frequently with endocrine problems, since there are fairly detailed tables for determining bone and dental ages and brief appendices which explain how several endocrine tests are carried out for thyroid and adrenal function. References are provided for the tests, but these are sometimes to the classic or first description of the test, neglecting later modifications. More recent references would have been helpful.
Postgraduate medical centres--Canterbury and Norwich.
Authors: F Roberts
Journal: BMJ (1966)

Will academic departments of general practice play an important part, and how many should there be ?Horder: These are very important as part of a network for teaching.There should be several in London, and one in every other teaching centre.I feel reasonably hopeful that this is going to happen.Smith: What about the existing postgraduate centres ?Horder: They could also produce courses, which would be local and within reach of young doctors.We have to plan for between 500 and 1,000 people coming into practice every year.Birdwood: What incentives should there be to take voca- tional training ?Horder: This is important.There are four main incen- tives.The first is enthusiaism.The second is higher pay, and at last we have got the principle agreed of a special allow- ance of £125 for 10 years.The third is Membership of the College.Finally, one would hope that if there is a little more competition to get into practice people wanting partners would look more carefully at the type of training they've had-though this is seldom realistic at the moment.
CME Forum
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17249: Impacts of Isometric Handgrip Exercise and Post-Exercise Circulatory Arrest on Hemodynamics and Left Ventricular Function in Heart Failure With Preserved Ejection Fraction
Authors: Keishi Moriwaki, Naoki Fujimoto, So Miyahara, Shusuke Fukuoka, Masaki Ishiyama, Taku Omori, Emiyo Sugiura, Kaoru Dohi, Masaaki Ito
Journal: Circulation (2018)

Introduction: Isometric handgrip (IHG) training at 30% maximal voluntary contraction (MVC) lowers blood pressure (BP) in patients with hypertension and healthy individuals. However, impacts of IHG and post-exercise circulatory arrest (PECA), which isolates the metaboreflex control, on left ventricular (LV) function and hemodynamics have been unclear in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Methods: Sixteen patients with HF (age 63±13 years, 5M:11F, 10HFpEF:6HFrEF) underwent invasive LV pressure-volume assessments using conductance catheter with microtip-manometer during 3min of IHG exercise at 30% MVC, followed by 3 min of PECA. Impacts of IHG and PECA on LV function and hemodynamics were evaluated and compared between HFpEF and HFrEF. Results: During 3 min of IHG at 30% MCV, heart rate increased by 10±8 bpm in HFpEF and by 14±6 bpm in HFrEF. IHG elevated LV end-systolic BP in both HFpEF (134±21 vs. 158±30 mmHg, p&lt;0.01) and HFrEF (119±30 vs. 142±31 mmHg, p&lt;0.01) with no change in stroke volume. There was a trend towards an increase in LV end-diastolic pressure in both groups (HFpEF:14±5 vs. 19±10 mmHg, HFrEF: 15±12 vs. 23±11 mmHg). Time constant of LV relaxation was unchanged by 3 min of IHG in HFpEF (52±14 vs. 54±15 ms), while it was prolonged in HFrEF (48±7 vs. 60±9 ms, p&lt;0.01, groupхtime interaction effect p=0.08). During PECA, LV end-systolic BP decreased in both groups and was maintained higher than baseline throughout PECA only in HFpEF. Conclusions: Although IHG exercise at 30% MVC for 3 min would elevate LV end-systolic and end-diastolic pressures, this IHG exercise has no detrimental effect on LV systolic and diastolic function, especially in HFpEF patients. Chronic effect of IHG training on BP and hemodynamics will need to be evaluated in HFpEF patients who often suffer from arterial hypertension.
SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.
Authors: Ulka N. Vaishampayan, Catherine Tangen, Abhishek Tripathi, Brian M. Shuch, Sumanta K. Pal, Pedro C. Barata, Alan Tan, Peggy Zuckerman, Edward Mayerson, Primo "Lucky" N. Lara, Neeraj Agarwal, Nicholas J. Vogelzang, Hyung Lae Kim, Ian Murchie Thompson
Journal: Journal of Clinical Oncology (2022)

TPS402 Background: Kidney cancer presenting with synchronous primary tumor and metastases has demonstrated shorter survival outcome, as compared to the patients relapsing later with metastases after nephrectomy. CARMENA trial demonstrated no change in overall survival with addition of nephrectomy to sunitinib therapy. Immune checkpoint based combination therapy has now become the standard of care in frontline setting for RCC. The role of cytoreductive nephrectomy (CN) or primary resection has not been evaluated in the setting of immune checkpoint based systemic therapy. The PROBE study design attempts to answer the question whether CN has an impact on overall survival outcomes in advanced RCC within the context of immune checkpoint based combination regimens. The underlying mechanism is that the broader antigen spread and higher neoantigen load enabled by the primary tumor would enhance the efficacy of the immune therapy. CN after initial systemic therapy will potentially enable eradication of the immune resistant clones within the primary. Methods: Eligible patients with primary tumor and metastases are treated with one of the FDA approved ICI based combinations: ipililumab and nivolumab, axitinib and pembrolizumab, or axitinib and avelumab. Cabozantinib + nivolumab and lenvatinib + pembrolizumab combinations are being added into the next amendment. Urology evaluation and response assessment is required. Randomization occurs between 10-14 weeks of therapy; 1:1 to receive CN followed by systemic therapy or to continue on systemic therapy. The primary endpoint is overall survival. We estimate the median survival from time of randomization for the non-surgical arm will be 25 months. The study hypothesis is that CN will result in improvement in OS outcomes in advanced synchronous RCC post-initial systemic immune checkpoint based combination therapy. With a sample size of 302 eligible, randomized participants (151 per arm) and a one-sided alpha = 0.025, the study has 85% power to detect a 47% improvement in median survival (HR = 0.68; 1/0.68 = 1.47) Clinical trial information: NCT04510597.
Hyperaldosteronism
Authors: G. C. Brill, B. Creamer, I. H. Mills, J. M. Pullan
Journal: BMJ (1960)

TREATMENT OF HYPERTENSION MEDICALJOURNAL with present methods of treatment.In some patients renal-clearance values remained unchanged, and it was thought that further deterioration in these patients may have been prevented by hypotensive treatment.We are grateful to Professor C. H. Stuart-Harris for advice during the preparation of this paper and for allowing us to investigate and treat patients under his care.We are indebted to Dr.
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
Authors: M. Pérol, E. Felip, U. Dafni, L. Polito, N. Pal, Z. Tsourti, T.G.N. Ton, D. Merritt, S. Morris, R. Stahel, S. Peters
Journal: Annals of Oncology (2022)
Neoantigens as potential vaccines in hepatocellular carcinoma
Authors: David Repáraz, Marta Ruiz, Diana Llopiz, Leyre Silva, Enric Vercher, Belén Aparicio, Josune Egea, Ibon Tamayo-Uria, Sandra Hervás-Stubbs, Jorge García-Balduz, Carla Castro, Mercedes Iñarrairaegui, Maria Tagliamonte, Angela Mauriello, Beatrice Cavalluzzo, Luigi Buonaguro, Charlotte Rohrer, Kathrin Heim, Catrin Tauber, Maike Hofmann, Robert Thimme, Bruno Sangro, Pablo Sarobe
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. Methods Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. Results Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. Conclusion These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies.
CHICAGO GYNÆCOLOGICAL SOCIETY.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prolonging utilization of systemic therapy in oligoprogressive metastatic renal cell carcinoma using stereotactic body radiation therapy.
Authors: Ramya Muddasani, Ameish Govindarajan, Sabrina Salgia, Nicholas Salgia, Zeynep Busra Zengin, Luis A Meza, Joann Hsu, Alex Chehrazi-Raffle, Nazli Dizman, Neal Shiv Chawla, Jasnoor Malhotra, Cristiane Decat Bergerot, Errol James Philip, Daniela V. Castro, Savita V. Dandapani, Nishita Tripathi, Nicolas Sayegh, Sumanta K. Pal
Journal: Journal of Clinical Oncology (2022)

336 Background: SBRT in indicated for the management of locally recurrent and oligometastatic mRCC as per National Comprehensive Cancer Network guidelines. Our study evaluates both the efficacy of radiotherapy (RT) in prolonging systemic treatment along with RT toxicity in the oligoprogressive RCC setting. Methods: A single institution retrospective data collection was performed in which we identified mRCC patients who experienced oligoprogression (defined as &lt;1 sites of progressive disease) while on an FDA approved systemic therapy and were concurrently treated with SBRT, while remaining on the same therapy. Clinicopathologic characteristics and SBRT-related data along with duration of systemic therapy (DOT) were collected. DOT was then quantified into two categories which included the duration of systemic therapy prior to oligoprogression (DOT[P]) and duration of systemic therapy after completion of SBRT (DOT[S]). The ratio of DOT[S]/DOT[P] was calculated to determine the impact of SBRT on systemic treatment prolongation. Results: 23 patients diagnosed with mRCC meeting criteria were identified, 91% (n = 21) with clear cell histology and 9% (n = 2) with papillary histology. At the time of oligoprogression, 15 patients (65%) were on immunotherapy, 7 patients (30%) were on targeted therapy, and 1 patient (5%) was on combination therapy. We noted the preponderance of patients were on a first-line therapy at the time of oligoprogression (n = 10, 43%). A median of 2 (range, 1-3) lesions were treated per patient, with lung being the most frequent site (n = 14, 40%). The median total dose of SBRT was 30 Gy (range, 27-50 Gy) with a median dose per fraction of 6 Gy (range, 3-12 Gy). SBRT related toxicities, all of which were grade &lt;2, were noted in 5 patients (22%), of which fatigue was the most frequent side effect (n = 3, 13%). Median DOT[S] was 13.4 months (range, 0.5-37.7 months) and the median DOT[P] was 12.8 months (range, 0.4-46.3 months). Results demonstrated a median DOT[S]/DOT[P] ratio to be 1.3 (range, 0.01-25.8). Conclusions: Based on our data, we discovered the addition of SBRT to systemic therapy during oligoprogression is not only well-tolerated, but that this treatment had clinical benefit in prolonging time on systemic therapy for patients with mRCC. The utilization of SBRT may prolong lines of therapy, thereby decreasing additional toxicities associated with exposure to new regimens.
Renal Biopsy
Authors: R. M. Kark
Journal: BMJ (1955)

NOVA ET VETERA MEDCAmJOURNAL53Company, Stollwerk and Co., of Cologne, in 1900-5 at the house in Georgstrasse.He says that there were automatic chocolate -machines, automatic music machines, electric pianos, weighing machines, the x-ray apparatus, automatic peasant bands, and a peepshow of the Frenchman Lumiere.In the cellar of the house a cinematograph apparatus func- tioned from time to time.Although Herr K. M. could not confirm the year 1896, Herr B. S. produced the answer to the key question.He could say for certain that he had seen the x-ray apparatus in 1896 because he was married that year, and he had gone to the showplace with his new brother-in-law.Further confirmation of the date 1896 came from a 78-year-old reader, Herr K. K., who became a soldier in 1897 and was quite definite that he went to the automaton show the year before.Dr. B. reported that in 1896 he already owned an x-ray apparatus in his practice, purchased through the firm of Nicolai, Leinstrasse, from Reiniger, Gebhard, and Schall.Herr 0. R. also reported that a doctor in Gehrden owned an x-ray apparatus in 1896.
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Authors: A. Passaro, N. Leighl, F. Blackhall, S. Popat, K. Kerr, M.J. Ahn, M.E. Arcila, O. Arrieta, D. Planchard, F. de Marinis, A.M. Dingemans, R. Dziadziuszko, C. Faivre-Finn, J. Feldman, E. Felip, G. Curigliano, R. Herbst, P.A. Jänne, T. John, T. Mitsudomi, T. Mok, N. Normanno, L. Paz-Ares, S. Ramalingam, L. Sequist, J. Vansteenkiste, I.I. Wistuba, J. Wolf, Y.L. Wu, S.R. Yang, J.C.H. Yang, Y. Yatabe, G. Pentheroudakis, S. Peters
Journal: Annals of Oncology (2022)
Cases from Private Practice
Authors: J. R. Wardell
Journal: BMJ (1847)

The following cases are not published as presenting features of very great rarity, but rather as being considered of a practical description, and with the nature and treatment of which the practitioner cannot become too familiar.Very uncommon examples of disease ae not tlhose from which the most useful benefit is derived; but cases that are at tines occurring, and the pathology and cure of which are, perhaps, not so well understood as many other affections, are par- tit-ularly eligible for being placed in a permanent form.there is no kind of medical instruction which is reallv so profitable as clinical teaching, which at once renders us acquainted with the often indescribable characters and multifarious features of disease, as witnessed in nature itself; and so it is that accurately detailed cases are, perhaps, really as instructive as auy kind of literature in our Journals, and it is much to be regretted that the country, as well as the metropolitan, and the private, as well as the hospital, practitioner, do not more commonly, in an accurate manner, study and faithfully record such cases of interest as from time to time fall beneath their notice.Every contribution, however small, to the commonwealth of medical literature, cannot fail to be of some service; and if the system of deducing and compiling facts were more generally pursued, there would be an aggregation of data highly valuable, and from which =oy useful and practical conclusions might be drawn.'The first example of disease now offered is that of an affection which is but occasionally met with in adults, and far more commonly occurs in children at an early age, nor was it until of late years fully understood, vi.
Abstract 17273: Long Non-Coding RNA Ppp1r1b Regulates Myogenic Differentiation Through Modulating Histone 3 Methylation
Authors: Xuedong Kang, Yan Zhao, Marlin Touma
Journal: Circulation (2018)

Introduction: Long noncoding RNAs (lncRNAs), emerged as critical epigenetic regulators of transcriptome, play important roles in cardiac development and might be targeted to treat human cardiomyocyte dysfunction. In our work, we identified a novel lncRNA that regulates myogenesis. Hypothesis: LncRNA Ppp1r1b regulates myogenesis by modulating Histone 3 methylation Methods: After treated with antisense oligonucleotides (GapmeR) or siRNA against Ppp1r1b-LncRNA, real time PCR and Western blot analyses were performed to examine the expression of myogenic and sarcomere genes. Chromatin immunoprecipitation (CHIP) was used to comparatively analyze gene specific histone modification level. RNA pull-down was employed to identify the protein molecules that interact with Ppp1r1b-LncRNA. Results: By silencing Ppp1r1b-LncRNA with GapmeR, C2C12, a skeletal myoblast cell line, did not develop fully differentiated myotubes, but tend to remain in a quiescent mono-nucleated status. In vivo analysis of GapmeR injected neonatal mouse heart and in vitro siRNA silenced human skeletal myoblasts further confirmed the important role of Ppp1r1b-LncRNA on myogenesis. Members of the MyoD family of muscle-specific transcription factors (MyoD and myogenin) failed to be up-regulated during myogenic differentiation when treated with Ppp1r1b-LncRNA specific GapmeR or siRNA. Key proteins essential for establishing and maintaining normal skeletal muscle architecture, including Tcap and Dystropnin, are also suppressed in Ppp1r1b LncRNA- deficient heart. Analysis of histone modification levels at Myogenin, MyoD1 and Tcap in C2C12 cells revealed more histone tri-methylation at these myogenic and sarcomere structural genes compared to untreated cells. Additional lncRNA- protein complex isolation has further revealed insight into the biological roles of Ppp1r1b-LncRNA. Conclusions: Our results support the role of Ppp1r1b-LncRNA in promoting myogenic differentiation. Ppp1r1b-lncRNA function is mediated by inhibiting histone methylation on promoters of multiple myogenic and sarcomere genes. In particular, the identification of EZH2 in pulled Pp1r1b LncRNA: protein complex implies that Polycomb repressive complex 2 (PRC2) is involved in Ppp1r1b-LncRNA modulated myoblast differentiation.
Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected
Authors: Marie Tré-Hardy, Roberto Cupaiolo, Alain Wilmet, Thomas Antoine-Moussiaux, Nicoleta Coman-Vlagea, Andrea Della Vecchia, Alexandra Horeanga, Emmanuelle Papleux, Marc Vekemans, Ingrid Beukinga, Laurent Blairon
Journal: Journal of Infection (2022)